Intriguingly, it has been demonstrated that management of chronic asthma by long-term use of CysLTR1 antagonists, like the U.S. Food and Drug Administration (FDA)-approved zafirlukast, significantly decreases the risk of several cancer types [20]. Here, CYSLTR1 is linked to chronic asthma.